Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 – Forge Therapeutics, Inc. (Forge) announced today that ...
Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug 14, 2019 – Forge Therapeutics, Inc. (Forge), a ...
Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics
San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica ...
Forge Therapeutics to present at the 18th Annual Needham & Company Healthcare Conference
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. ...
Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that it ...
Forge achieves carb-x milestone to advance its lpxc antibiotic to treat infections caused by the world’s deadliest ‘superbugs’
-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San Diego, California, August 1, 2018 – Forge Therapeutics, ...
Forge announces presentations at upcoming scientific and industry meetings
2018 BIO International, ASM Microbe, and GRC Metals in Medicine San Diego, California, May 21, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology ...
Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting
San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David ...
Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference
-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, ...
Forge Co-founder Presents New Approaches to Treat Infections at the 255th American Chemical Society National Meeting
San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that Professor ...